Neovasc Inc. announced that it will report financial results for the year ended December 31, 2017.
VANCOUVER, March 21, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.
Conference Call & Webcast
Wednesday, March 28th @ 4:30pm Eastern Time
Domestic: 800-281-7973
International: 323-794-2093
Passcode: 4395026
Webcast: http://public.viavid.com/index.php?id=128910
Replays available through April 10:
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 4395026
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
